这是一篇来自已证抗体库的有关
人类 PMS2的综述，是根据16篇发表使用所有方法的文章归纳的。这综述旨在帮助来邦网的访客找到最适合PMS2 抗体。
PMS2 同义词: HNPCC4; MLH4; PMS2CL; PMSL2
北京傲锐东源
| 小鼠 单克隆（OTI2G5） | - 免疫组化-石蜡切片; 人类; 1:150; 图 1
| 北京傲锐东源 PMS2抗体（zhongshan jiqiao, OTI2G5)被用于被用于免疫组化-石蜡切片在人类样本上浓度为1:150 (图 1). Cancer Med (2017) ncbi |
| 小鼠 单克隆（OTI2G5） | - 免疫组化-石蜡切片; 人类; 1:150; 图 1
| 北京傲锐东源 PMS2抗体（zhongshan jiqiao, OTI2G5)被用于被用于免疫组化-石蜡切片在人类样本上浓度为1:150 (图 1). PLoS ONE (2017) ncbi |
艾博抗（上海）贸易有限公司
| domestic rabbit 单克隆（EPR3947） | | 艾博抗（上海）贸易有限公司 PMS2抗体（Abcam, ab110638)被用于被用于免疫印迹在人类样本上 (图 1s1c). elife (2019) ncbi |
丹科医疗器械技术服务（上海）有限公司
| domestic rabbit 单克隆（EP51） | | 丹科医疗器械技术服务（上海）有限公司 PMS2抗体（Dako, IR087)被用于被用于免疫组化-石蜡切片在人类样本上 (图 1). Cancer Manag Res (2020) ncbi |
| domestic rabbit 单克隆（EP51） | | 丹科医疗器械技术服务（上海）有限公司 PMS2抗体（Dako, M3647)被用于被用于免疫组化-石蜡切片在人类样本上浓度为1:50 (表 1). Br J Cancer (2016) ncbi |
Cell Marque
| 小鼠 单克隆（MRQ-28） | - 免疫组化-石蜡切片; 人类; 1:50; 图 1c
| Cell Marque PMS2抗体（Cell Marque, MRQ-28288 M-15)被用于被用于免疫组化-石蜡切片在人类样本上浓度为1:50 (图 1c). Acta Neuropathol Commun (2020) ncbi |
碧迪BD
| 小鼠 单克隆（A16-4） | | 碧迪BD PMS2抗体（BD Biosciences, 556415)被用于被用于免疫印迹在人类样本上浓度为1:2500 (图 4a). elife (2019) ncbi |
| 小鼠 单克隆（A16-4） | | 碧迪BD PMS2抗体（Abcam, 556415)被用于被用于免疫组化在人类样本上浓度为1:100 (图 s4b). Nat Med (2016) ncbi |
| 小鼠 单克隆（A16-4） | | 碧迪BD PMS2抗体（BD Pharmingen, A16-4)被用于被用于免疫组化在人类样本上浓度为1:100. JAMA Oncol (2016) ncbi |
| 小鼠 单克隆（A16-4） | - 免疫印迹基因敲除验证; 小鼠; 1:500; 图 4a
| 碧迪BD PMS2抗体（BD Biosciences, 556415)被用于被用于免疫印迹基因敲除验证在小鼠样本上浓度为1:500 (图 4a). DNA Repair (Amst) (2016) ncbi |
| 小鼠 单克隆（A16-4） | | 碧迪BD PMS2抗体（BD Biosciences, A16.4)被用于被用于免疫组化在人类样本上浓度为1:100. Virchows Arch (2015) ncbi |
| 小鼠 单克隆（A16-4） | | 碧迪BD PMS2抗体（BD, A16-4)被用于被用于免疫组化在人类样本上浓度为1:100. Gynecol Oncol (2015) ncbi |
| 小鼠 单克隆（A16-4） | | 碧迪BD PMS2抗体（BD Pharmingen, 556415)被用于被用于免疫组化-石蜡切片在人类样本上. Cancer Genet (2014) ncbi |
| 小鼠 单克隆（A16-4） | | 碧迪BD PMS2抗体（BD Biosciences, 556415)被用于被用于免疫印迹在人类样本上. J Biol Chem (2014) ncbi |
| 小鼠 单克隆（A16-4） | | 碧迪BD PMS2抗体（PharMingen, A16-4)被用于被用于免疫组化-石蜡切片在人类样本上浓度为1:300. PLoS ONE (2014) ncbi |
| 小鼠 单克隆（A16-4） | | 碧迪BD PMS2抗体（BD Biosciences Pharmingen, A16-4)被用于被用于免疫组化-石蜡切片在人类样本上浓度为1:100. PLoS ONE (2013) ncbi |
Shao W, Wang C, Wang L, Xiao F, Xiao D, Yang H,
et al. A Hereditable Mutation of MSH2 Gene Associated with Lynch Syndrome in a Five Generation Chinese Family. Cancer Manag Res. 2020;12:1469-1482
pubmed 出版商 McCord M, Steffens A, Javier R, Kam K, McCortney K, Horbinski C. The efficacy of DNA mismatch repair enzyme immunohistochemistry as a screening test for hypermutated gliomas. Acta Neuropathol Commun. 2020;8:15
pubmed 出版商 Abildgaard A, Stein A, Nielsen S, Schultz Knudsen K, Papaleo E, Shrikhande A,
et al. Computational and cellular studies reveal structural destabilization and degradation of MLH1 variants in Lynch syndrome. elife. 2019;8:
pubmed 出版商 Pech M, Fong L, Villalta J, Chan L, Kharbanda S, O Brien J,
et al. Systematic identification of cancer cell vulnerabilities to natural killer cell-mediated immune surveillance. elife. 2019;8:
pubmed 出版商 Li P, Xiao Z, Braciak T, Ou Q, Chen G, Oduncu F. Impact of age and mismatch repair status on survival in colorectal cancer. Cancer Med. 2017;6:975-981
pubmed 出版商 Li P, Xiao Z, Braciak T, Ou Q, Chen G, Oduncu F. A relationship to survival is seen by combining the factors of mismatch repair status, tumor location and age of onset in colorectal cancer patients. PLoS ONE. 2017;12:e0172799
pubmed 出版商 Park J, Powell A, Roxburgh C, Horgan P, McMillan D, Edwards J. Mismatch repair status in patients with primary operable colorectal cancer: associations with the local and systemic tumour environment. Br J Cancer. 2016;114:562-70
pubmed 出版商 Beltran H, Prandi D, Mosquera J, Benelli M, Puca L, Cyrta J,
et al. Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. Nat Med. 2016;22:298-305
pubmed 出版商 Taieb J, Zaanan A, Le Malicot K, Julie C, Blons H, Mineur L,
et al. Prognostic Effect of BRAF and KRAS Mutations in Patients With Stage III Colon Cancer Treated With Leucovorin, Fluorouracil, and Oxaliplatin With or Without Cetuximab: A Post Hoc Analysis of the PETACC-8 Trial. JAMA Oncol. 2016;2:643-653
pubmed 出版商 Fischer J, Dudley S, Miller A, Liskay R. An intact Pms2 ATPase domain is not essential for male fertility. DNA Repair (Amst). 2016;39:46-51
pubmed 出版商 Vanoli A, Argenti F, Vinci A, La Rosa S, Viglio A, Riboni R,
et al. Hepatoid carcinoma of the pancreas with lymphoid stroma: first description of the clinical, morphological, immunohistochemical, and molecular characteristics of an unusual pancreatic carcinoma. Virchows Arch. 2015;467:237-45
pubmed 出版商 Geels Y, van der Putten L, van Tilborg A, Lurkin I, Zwarthoff E, Pijnenborg J,
et al. Immunohistochemical and genetic profiles of endometrioid endometrial carcinoma arising from atrophic endometrium. Gynecol Oncol. 2015;137:245-51
pubmed 出版商 Vilar E, Mork M, Cuddy A, Borràs E, Bannon S, Taggart M,
et al. Role of microsatellite instability-low as a diagnostic biomarker of Lynch syndrome in colorectal cancer. Cancer Genet. 2014;207:495-502
pubmed 出版商 Lin B, Gupta D, Heinen C. Human pluripotent stem cells have a novel mismatch repair-dependent damage response. J Biol Chem. 2014;289:24314-24
pubmed 出版商 Koppensteiner R, Samartzis E, Noske A, von Teichman A, Dedes I, Gwerder M,
et al. Effect of MRE11 loss on PARP-inhibitor sensitivity in endometrial cancer in vitro. PLoS ONE. 2014;9:e100041
pubmed 出版商 Egoavil C, Alenda C, Castillejo A, Paya A, Peiro G, Sanchez Heras A,
et al. Prevalence of Lynch syndrome among patients with newly diagnosed endometrial cancers. PLoS ONE. 2013;8:e79737
pubmed 出版商
